TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A University of Oulu team tested a treatment combining temporary blood-pressure reduction with whole-body vibration in 29 healthy adults. Brain-derived proteins, including beta-amyloid, rose in participants’ blood after treatment, a finding the researchers interpret as evidence of increased clearance; whether it benefits people with dementia or prevents disease is unknown.
Researchers at the University of Oulu and Oulu University Hospital report that a combination of blood-pressure-lowering medication and whole-body vibration was associated with increased levels of dementia-linked proteins in the blood of 29 healthy adults. Published in Nature Communications on November 3, the small study suggests the intervention may increase the brain’s clearance of soluble proteins, but it does not show that the treatment prevents dementia or improves memory.
The team examined participants using multimodal MRI, physiological measurements and blood tests for proteins originating in the brain. After treatment, blood levels of beta-amyloid 40 and 42, as well as GFAP, increased. The researchers also reported changes in brain fluid flow and protein concentrations on MRI, particularly around large veins. They interpret the combined results as evidence that more soluble brain-derived proteins moved into the bloodstream.
The intervention paired medication that temporarily lowered blood pressure with rhythmic whole-body vibration intended to activate Piezo1 channels in blood vessels. According to the study, the medication strengthened slow brain pulsations associated with fluid movement. The vibration component was selected based partly on earlier animal research linking Piezo1 activation to changes in fluid drainage around the brain.
The findings are reported as an association with increased protein efflux, not as proof that harmful proteins were removed in a way that changes disease risk. The study involved healthy adults and measured short-term biological responses. It did not establish whether the treatment is effective or safe as a repeated intervention, or whether it changes symptoms or long-term outcomes in people with neurodegenerative disease.
Testing a New Route for Brain Clearance
Many disorders that cause dementia, including Alzheimer’s disease, are associated with the gradual accumulation of proteins in the brain. The study tests whether the body’s own fluid-clearance processes can be influenced while people are awake, rather than relying only on the changes in blood pressure and brain pulsations that naturally occur during sleep.
If later research confirms the effect and establishes a safe, practical way to use it, the approach could give researchers a new direction to investigate for people at risk of neurodegenerative disease. For now, the significance is scientific rather than clinical: protein levels in blood and MRI measures changed, but no dementia prevention or treatment benefit was demonstrated.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
LEVOIT Air Purifier for Home, Pets, Bedroom, Smart WiFi
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
As an affiliate, we earn on qualifying purchases.
From Sleep Biology to Awake Treatment
The brain’s clearance activity is known to be more active during sleep. As people fall asleep, blood pressure typically drops and slow vascular and respiratory pulsations become stronger. These changes help move cerebrospinal fluid through brain tissue, supporting the removal of waste products.
The Oulu study drew on previous animal studies in which temporarily lowering blood pressure was associated with increased clearance of cerebrospinal fluid and large molecules. Other animal research has linked Piezo1 activation to greater flow through lymphatic vessels around the brain and lower beta-amyloid burden. Those studies provided a rationale for testing the combined approach in people, but results in animals do not establish a benefit in human patients.
The human study’s results were published in Nature Communications under the title “Vasomechanic treatment is associated with increased efflux of human brain proteins.” The authors used blood biomarkers alongside MRI and physiological measurements to examine the response.
Clinical Benefits Remain Untested
The findings do not show that the intervention lowers the amount of protein deposited in brain tissue, prevents dementia, or slows cognitive decline. Increased blood levels were interpreted by the authors as a sign of protein movement out of the brain, but the study does not establish long-term effects or whether the change improves health.
The report describes 29 healthy adult volunteers, but the supplied study summary does not give detailed information about participant ages, the treatment’s duration, the size of each protein increase, or how long the changes lasted. It also does not establish the risks of repeating the treatment, particularly for people with memory impairment or other health conditions. Those questions require further research.
Follow-Up Studies in Memory Impairment
Kiviniemi said the team is planning follow-up research with other experts to investigate possible benefits in people with early-stage memory impairment. Those studies will need to establish whether the measured changes can be reproduced in patients, how long they last and whether they correspond to meaningful clinical outcomes.
Until such results are available, the treatment remains a research approach tested in healthy volunteers, not an established prevention or therapy for dementia. The next evidence to watch for is whether trials in people with memory problems show both a sustained biological effect and a measurable benefit to patients.
Key Questions
What treatment did the researchers test?
They combined temporary blood-pressure-lowering medication with rhythmic whole-body vibration intended to affect blood-vessel function.
What changed after treatment?
Blood levels of brain-derived proteins, including beta-amyloid 40 and 42 and GFAP, increased. MRI and physiological measurements also showed changes the researchers associated with fluid movement.
Does the study show that the treatment prevents Alzheimer’s disease?
No. It involved 29 healthy adults and measured short-term biological responses. It did not test whether the intervention prevents dementia or improves patients’ symptoms.
What research is planned next?
The researchers say they are planning follow-up studies to examine possible effects in people with early-stage memory impairment.
Source: news-medical.net
